Sun Pharma receives USFDA nod for generic drug

MUMBAI: Pharma major Sun Pharmaceutical Industries on Tuesday said it has received the final approval from the US Food and Drug Administration (USFDA) to market the generic version of Novartis Exelon capsules.

It is primarily used for treating Alzheimer's and Parkinson's diseases. In a filing to the Bombay Stock Exchange, the firm informed that the USFDA had granted the final approval for its Abbreviated New Drug Application (ANDA) to market the generic version of Novartis Exelon capsules.

The generic version of rivastgmine tartrate capsules (Exelon) comes in four strengths, 1.5 mg (base), 3 mg (base), 4.5 mg (base) and 6 mg (base). Rivastgmine tartrate is indicated for the treatment of mild to moderate dementia of the Alzheimer's type and for the treatment of mild to moderate dementia associated with Parkinson's disease.

Shares of the company closed at Rs 1007.5, up 2.84 per cent at the BSE.